07:29 AM EST, 12/06/2024 (MT Newswires) -- AstraZeneca ( AZN ) said late Thursday that a pooled analysis of phase 2 and phase 3 trials of datopotamab deruxtecan, or Dato-DXd, showed "clinically meaningful" tumor response in patients with previously treated advanced or metastatic non-small cell lung cancer.

Datopotamab deruxtecan is an antibody drug conjugate discovered by Japan's Daiichi Sankyo and being jointly developed with AstraZeneca ( AZN ).

The drug showed a confirmed objective response rate of 42.7% in a pooled analysis of 117 patients with EGFR-mutated non-small cell lung cancer, the company said, adding that researchers observed 4.3% complete responses, 38.5% partial responses, and 41% of stable disease.

"These results show that datopotamab deruxtecan can improve outcomes for patients with EGFR-mutated non-small cell lung cancer whose disease has become resistant to current treatments," said Susan Galbraith, executive vice president for oncology research & development at AstraZeneca ( AZN ).